Desmoglein 2-directed chimeric antigen receptor (CAR) constructs and methods of use
AssigneeThomas Jefferson University
InventorsAdam Eugene Snook, My Georgia Mahoney, Robert Devlin Carlson
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to Dsg2 binding molecules, nucleic acid molecules encoding the Dsg2 binding molecules and compositions comprising the same and methods of use thereof for treating or preventing cancer.
Claims21
A composition comprising a chimeric antigen receptor (CAR) molecule comprising a domain that specifically binds to Dsg2, wherein the domain that specifically binds to Dsg2 comprises an antibody or fragment thereof selected from the group consisting of:
- a) an antibody or fragment thereof comprising a variable heavy chain sequence comprising the CDR sequences of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:
- 6 and a variable light chain sequence comprising the CDR sequences of SEQ ID NO:
- 10, SEQ ID NO:12 and SEQ ID NO:
- 14;
- and
- b) an antibody or fragment thereof comprising a variable heavy chain sequence comprising the CDR sequences of SEQ ID NO:18, SEQ ID NO:20 and SEQ ID NO:
- 22 and a variable light chain sequence comprising the CDR sequences of SEQ ID NO:
- 26, SEQ ID NO:28 and SEQ ID NO:30.
A composition comprising a nucleic acid molecule, or combination of nucleic acid molecules, encoding a CAR molecule comprising a domain that specifically binds to Dsg2 wherein the domain that specifically binds to Dsg2 comprises an antibody or fragment thereof selected from the group consisting of:
- a) an antibody or fragment thereof comprising a variable heavy chain sequence comprising the CDR sequences of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:
- 6 and a variable light chain sequence comprising the CDR sequences of SEQ ID NO:
- 10, SEQ ID NO:
- 12 and SEQ ID NO:
- 14;
- and
- b) an antibody or fragment thereof comprising a variable heavy chain sequence comprising the CDR sequences of SEQ ID NO:18, SEQ ID NO:20 and SEQ ID NO:
- 22 and a variable light chain sequence comprising the CDR sequences of SEQ ID NO:
- 26, SEQ ID NO:28 and SEQ ID NO:30.
A chimeric antigen receptor comprising a domain that specifically binds to Dsg2, wherein the domain that specifically binds to Dsg2 comprises an antibody or fragment thereof comprising a variable heavy chain sequence comprising the CDR sequences of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6 and a variable light chain sequence comprising the CDR sequences of SEQ ID NO:10, SEQ ID NO:12 and SEQ ID NO:14.
Dependencies are inferred from the claim text.